Complement inhibition attenuates human lung transplant reperfusion injury: a multicenter trial
MR Zamora, RD Davis, SH Keshavjee, L Schulman… - Chest, 1999 - journal.chestnet.org
Materials and Methods We performed a randomized, double-blinded, placebo-controlled
multicenter trial at five North American LTx centers. Fifty-nine patients received either TP10
(10 mg/kg, n= 29) or placebo (P, n= 30) prior to reperfusion of the lung allograft. This dose
achieves> 90% C inhibition for 24 to 48 h; activity returns to normal by 72 h. Indications for
LTx were emphysema (66%), pulmonary fibrosis (15%), pulmonary hypertension (14%), and
other (5%). Patients with cystic fibrosis were excluded from the trial. Outcome variables were …
multicenter trial at five North American LTx centers. Fifty-nine patients received either TP10
(10 mg/kg, n= 29) or placebo (P, n= 30) prior to reperfusion of the lung allograft. This dose
achieves> 90% C inhibition for 24 to 48 h; activity returns to normal by 72 h. Indications for
LTx were emphysema (66%), pulmonary fibrosis (15%), pulmonary hypertension (14%), and
other (5%). Patients with cystic fibrosis were excluded from the trial. Outcome variables were …